 REDWOOD CITY, CA ACCESSWIRE June 23, 2020 Avinger, Inc. AVGR, a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease PAD, today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be 5.4 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The proposed offering equates to 20 million shares of the Companys common stock at a price of 0.27 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include research and development of the Companys Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of sales and marketing organizations and efforts, intellectual property protection and enforcement and capital expenditures. 